Table 1 Baseline characteristics.

From: Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences

Variable

All

AAM

EAM

P value

Number of patients

1152

596

556

 

Age at surgery, mean (IQR)

63.8 (58, 68)

63.3 (58, 67.7)

64 (58, 68.7)

0.083

Preoperative PSA, median (IQR)

7 (5, 11)

7.9 (5.6, 12)

6.5 (4.8, 10)

<0.001

RP grade group, n (%)

 1

53 (4.6)

35 (5.9)

18 (3.2)

0.024

 2

639 (55.5)

333 (55.9)

306 (55)

 

 3

281 (24.4)

131 (22)

150 (27)

 

 4

79 (6.9)

49 (8.2)

30 (5.4)

 

 5

100 (8.7)

48 (8.1)

52 (9.4)

 

pT stage, n (%)

 T2

645 (56\)

322 (54)

323 (58)

0.001

 T3a

274 (23.7)

130 (21.8)

144 (26)

 

 T3b

149 (12.9)

88 (14.7)

61 (11)

 

 T4

18 (1.5)

16 (2.7)

2 (0.3)

 

pN stage, n (%)

 N1

41 (3.6%)

21 (3.5)

20 (3.6)

>0.999

 N0

51 (4.4%)

27 (4.5)

24 (4.3)

 

CAPRA-S riska

 Low

208 (32.6)

62 (22.4)

146 (40.4)

<0.001

 Intermediate

287 (45)

126 (45.5)

161 (44.6)

 

 High

143 (32.4)

89 (32.1)

54 (15)

 

Decipher score, median (IQR)

0.52 (0.36, 0.66)

0.54 (0.38, 0.68)

0.50 (0.34, 0.65)

0.14

Decipher group, n (%)

 Low

455 (39.5)

215 (36)

240 (43.2)

0.04

 Average

184 (15.9)

153 (25.8)

131 (23.5)

 

 High

413 (35.8)

228 (38.2)

185 (33.2)

 
  1. AAM African-American men, EAM European-American men, CAPRA-S cancer of the prostate risk assessment postsurgical, IQR interquartile range, PSA prostate-specific antigen, RP radical prostatectomy.
  2. Bold values indicate statistical significance p < 0.05.
  3. aMissing data.